摘要
目的分析糖尿病合并冠心病患者实施瑞舒伐他汀联合替米沙坦治疗的有效性。方法65例糖尿病合并冠心病患者,使用电脑随机分组原则分为参照组(32例)与治疗组(33例)。参照组患者实施瑞舒伐他汀治疗,治疗组患者在参照组基础上联合替米沙坦治疗。比较两组患者治疗前、治疗1个月后的胰岛素抵抗指数(HOMA-IR)、糖化血红蛋白(HbA1c)、空腹血糖、餐后2 h血糖、低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)、左室射血分数(LVEF)。结果治疗1个月后,治疗组的HOMA-IR(2.80±0.46)、HbA1c(6.22±0.62)%、空腹血糖(6.55±1.49)mmol/L、餐后2 h血糖(8.10±1.45)mmol/L低于参照组的(3.30±0.55)、(7.83±0.78)%、(8.57±1.63)mmol/L、(10.27±1.67)mmol/L(P<0.05)。治疗1个月后,治疗组的LDL-C(2.42±0.32)mmol/L、TG(2.02±0.37)mmol/L低于参照组的(3.20±0.38)、(2.63±0.55)mmol/L,HDL-C(1.49±0.23)mmol/L高于参照组的(1.22±0.20)mmol/L(P<0.05)。治疗1个月后,治疗组的LVEDD(51.63±9.50)mm、LVESD(40.38±9.32)mm短于参照组的(57.38±9.89)、(46.10±9.56)mm,LVEF(62.73±8.50)%高于参照组的(52.25±9.10)%(P<0.05)。结论瑞舒伐他汀联合替米沙坦用于糖尿病合并冠心病治疗中的疗效十分显著,不仅能降低和稳定患者血糖水平,还能改善机体脂蛋白及心肌缺血情况,预防心脏意外事件的发生,改善患者预后。
Objective To analyze the effectiveness of telmisartan in combination with rosuvastatin in the treatment of patients with diabetes complicated with coronary artery disease.Methods 65 patients with diabetes complicated with coronary heart disease were divided into the reference group(32 cases)and the treatment group(33 cases)by computer randomization.Patients in the reference group were treated with rosuvastatin,and patients in the treatment group were treated with telmisartan based on the reference group.Patients in both groups were compared in terms of insulin resistance index(HOMA-IR),glycosylated hemoglobin(HbA1c),fasting blood glucose and 2 h postprandial glucose,low density lipoprotein cholesterol(LDL-C),triglyceride(TG),high density lipoprotein cholesterol(HDL-C),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD),left ventricular ejection fraction(LVEF)before treatment and 1 month after treatment.Results 1 month after treatment,the treatment group had HOMA-IR of(2.80±0.46),HbA1c of(6.22±0.62)%,fasting blood glucose of(6.55±1.49)mmol/L,and 2 h postprandial blood glucose of(8.10±1.45)mmol/L,which were lower than(3.30±0.55),(7.83±0.78)%,(8.57±1.63)mmol/L,and(10.27±1.67)mmol/L in the reference group(P<0.05).After 1 month of treatment,the treatment group had LDL-C of(2.42±0.32)mmol/L and TG of(2.02±0.37)mmol/L,which were lower than(3.20±0.38)and(2.63±0.55)mmol/L in the reference group;the treatment group had a higher HDL-C of(1.49±0.23)mmol/L than(1.22±0.20)mmol/L in the reference group(P<0.05).After 1 month of treatment,the treatment group had LVEDD of(51.63±9.50)mm and LVESD of(40.38±9.32)mm,which were shorter than(57.38±9.89)and(46.10±9.56)mm in the reference group;the treatment group had a higher LVEF of(62.73±8.50)%than(52.25±9.10)%in the reference group(P<0.05).Conclusion Rosuvastatin combined with telmisartan is effective in the treatment of diabetes complicated with coronary heart disease,which can not only reduce and stabilize the blood glucose level of patients,but also improve the lipoprotein and myocardial ischemia,prevent the occurrence of cardiac accidents,and improve the prognosis of patients.
作者
于建勇
郑良宏
YU Jian-yong;ZHENG Liang-hong(Baoying County Traditional Chinese Medicine Hospital,Yangzhou 225800,China)
出处
《中国现代药物应用》
2025年第10期78-81,共4页
Chinese Journal of Modern Drug Application
关键词
糖尿病
冠心病
替米沙坦
瑞舒伐他汀
心肌缺血
血糖指标
Diabetes
Coronary artery disease
Telmisartan
Rosuvastatin
Myocardial ischemia
Blood glucose indicators
